New Biomarkers for Detecting Linked Heart, Kidney, Liver, and Metabolic Disease — and How GLP-1 Drugs Fit In

Narrative review analyzing the pathophysiology of CRHM syndrome and evaluating emerging biomarkers based on published literature. The review synthesizes evidence on disease mechanisms (chronic inflammation, insulin resistance, oxidative stress, endothelial dysfunction) and assesses the clinical utility of novel biomarkers for risk stratification and treatment guidance.

Heart, kidney, liver, and metabolic diseases rarely exist in isolation — they drive each other in a vicious cycle that current medicine often treats organ by organ. This framework pushes for integrated diagnosis and treatment, with biomarkers that capture the multi-organ nature of disease. Linking these biomarkers to specific therapies like GLP-1 agonists could move medicine toward truly personalized multi-organ care.

The concept of CRHM syndrome reflects a growing recognition in medicine that metabolic diseases are systemic, not organ-specific. By adding the liver to the cardiovascular-kidney-metabolic framework, this review acknowledges the central role of hepatic metabolism in driving multi-organ dysfunction. The emphasis on biomarker-guided use of GLP-1 drugs and SGLT2 inhibitors aligns with the broader trend toward precision medicine in cardiometabolic care.

As a narrative review, this paper synthesizes existing evidence but does not generate new data. The clinical integration of the discussed biomarkers remains limited — most are not yet standard in clinical practice. The review does not provide specific thresholds or cutoff values for when biomarker levels should trigger particular treatments. Long-term prospective validation studies are needed for most of the emerging biomarkers discussed.